标准化「快速」:应用临床痴呆评定量表定义快速进展性痴呆
研究提出基于临床痴呆评定量表(CDR)的快速进展性痴呆(RPD)定义:症状出现1年内达痴呆(全局CDR≥1)或2年内达失能(全局CDR≥2)。在RaPID队列248例中185例(74.6%)符合,NACC数据集20418例认知障碍者中836例(4.1%)符合。RPD组CDR-SB年变化显著更快。该定义能早期识别多种病因的RPD。
要点
- 基于CDR的RPD定义:1年内CDR≥1或2年内CDR≥2。
- RaPID队列中74.6%疑似RPD符合该定义,病因以自身免疫性、神经变性、朊蛋白病为主。
- RPD组CDR-SB年变化显著高于非RPD组,支持定义的有效性。
核心结论
- 基于CDR的RPD定义能有效识别症状早期、病因谱广泛的快速进展性痴呆个体。
研究设计与样本
- 前瞻性RaPID队列来自Mayo Clinic Florida和Washington University in St. Louis的住院和门诊疑似RPD患者,共248例。
- 回顾性分析46个研究中心参与的NACC数据集,共20418例认知障碍参与者。
主要发现
- RaPID队列中185/248(74.6%)符合CDR-based RPD定义,中位发病年龄68.8岁(范围22.0-90.7),女性45.4%。
- RaPID队列RPD病因:自身免疫性55/185(29.7%)、神经变性51/185(27.6%)、朊蛋白病35/185(18.9%)。
- NACC数据集中836/20418(4.1%)符合RPD定义,中位发病年龄74岁(范围24-103),女性57.1%;神经变性疾病为主,阿尔茨海默病485/836(58.0%)。
- RPD组CDR-SB年变化:RaPID 14.4±5.3 vs 4.3±4.3,p<0.001;NACC 6.7±3.1 vs 1.7±1.4,p<0.001。
- 范围综述识别22项研究应用了10种不同的RPD定义。
关键数值与推荐
- RPD定义:症状出现1年内达痴呆(全局CDR≥1)或2年内达失能(全局CDR≥2)。
临床怎么用
- 该CDR-based定义可在多中心、多场景中早期识别RPD,资源需求低。
- 需培训并花费时间可靠实施CDR,可能限制该定义的应用。
局限性
- 需在额外队列中验证以支持普遍性。
- CDR实施需要培训和时间的限制可能影响应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Rapidly progressive dementia (RPD) accounts for 3%-4% of dementia cases yet presents a disproportionate clinical challenge given the wide differential diagnosis and the need to quickly identify potentially treatment-responsive causes. The lack of a standardized definition of RPD challenges generalization of published findings and precludes multisite studies. We sought to determine whether a standardized definition, based on the Clinical Dementia Rating (CDR), could reliably distinguish individuals with a broad spectrum of causes of RPD early in the symptomatic course. METHODS: RPD was defined as dementia (global CDR ≥1) developing within 1 year or incapacitation (global CDR ≥2) within 2 years of symptom onset. Patients with suspected RPD were referred from inpatient and outpatient settings at Mayo Clinic in Florida (Jacksonville, FL) and Washington University in St. Louis (Saint Louis, MO) and prospectively evaluated (RaPID cohort). Retrospective data from participants assessed across 46 research centers were also analyzed (National Alzheimer's Coordinating Center [NACC] data set). Characteristics and rates of progression (main outcome) were compared between typically progressive and RPD. Univariable and multivariable analyses were performed using Mann-Whitney U/Kruskal-Wallis (continuous) and Fisher exact/χ2 tests (binary), respectively. Our definition of RPD was compared against definitions identified through a scoping review conducted using a validated 6-stage approach. RESULTS: In the RaPID cohort, 185 of 248 (74.6%) patients met our CDR-based RPD definition (median [range] age-at-symptom onset: 68.8 years [22.0-90.7]; 45.4% female). Autoimmune (55/185, 29.7%), neurodegenerative (51/185, 27.6%), and prion diseases (35/185, 18.9%) predominated. Among 20,418 NACC participants with cognitive impairment, 836 (4.1%) met our RPD definition (median [range] age-at-symptom onset: 74 years [24-103]; 57.1% female). Neurodegenerative diseases predominated, especially Alzheimer disease (485/836, 58.0%). Individuals with RPD declined substantially faster (ΔCDR sum-of-boxes/year: RaPID, 14.4 ± 5.3 vs 4.3 ± 4.3, p < 0.001; NACC, 6.7 ± 3.1 vs 1.7 ± 1.4, p < 0.001). Our scoping review identified 22 studies that applied 10 distinct definitions of RPD. Uniquely, our CDR-based definition clearly distinguished individuals with a broad spectrum of causes of RPD, assessed across multiple sites/settings, supporting early diagnosis with minimal resource requirements. DISCUSSION: The CDR-based definition of RPD effectively identified individuals with a broad spectrum of causes of RPD early in the symptomatic course. The need for training and time to reliably administer the CDR may limit application of the proposed definition of RPD. Validation in additional cohorts is required to support generalizability.
引用
- Satyadev N, Piura YD, Tipton PW, et al. Standardizing "Rapid": Applying the Clinical Dementia Rating to Define Rapidly Progressive Dementia. Neurology. 2025. PMID: 41397211. doi:10.1212/WNL.0000000000214439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。